The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis
By: Andreas Maetzel, Murray Krahn, Gary Naglie.
Contributors: Krahn, Murray.; Maetzel, Andreas.; Naglie, Gary.; Canadian Coordinating Office for Health Technology Assessment.
Series: Technology report -- issue 23; Technology report (Canadian Coordinating Office for Health Technology Assessment) -- issue 23.
Publisher: Canadian Coordinating Office for Health Technology Assessment
Published: 2002
Place of publication: Ottawa, Ont
Language: eng
Number of pages: 39
Subjects: Arthritis, Rheumatoid -- drug therapy.; Celecoxib -- Therapeutic use -- Cost effectiveness.; Cost-Benefit Analysis.; Cyclooxygenase 2 -- Inhibitors -- Cost effectiveness.; Cyclooxygenase Inhibitors -- therapeutic use.; Nonsteroidal anti-inflammatory agents -- Cost effectiveness.; Osteoarthritis -- Chemotherapy -- Cost effectiveness.; Osteoarthritis -- drug therapy.; Rheumatoid arthritis -- Chemotherapy -- Cost effectiveness.; Rofecoxib -- Therapeutic use -- Cost effectiveness.
Notes: Companion v. to: Economic assessment / A. Maetzel, M.D. Krahn, G. Naglie. 2002.

"January 2002"

Includes bibliographical references (p. 35-39).